The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK (Reuters) -Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic ...

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge. The case ...

Novartis has been boosted by data from a new study which shows that its new combination antihypertensive Exforge lowers blood pressure in twice as many patients than those on amlodipine alone.

The FDA has approved Novartis‘ Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an ...

Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in separate settlements with direct purchasers, ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Exforge HCT contains the active ingredients Amlodipine Besilate, ...

Deal is part of $245 million package announced last year Novartis, Endo unit accused of conspiring to keep competitors out Feb 23 (Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million ...

NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S), opens new tab said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in ...